Zachary Smith, DO

Associate Professor

Request an Appointment

Location

Gastroenterology and Hepatology - Froedtert Hospital
8850 William Coffey Drive
Milwaukee, WI 53226

Specialties

Gastroenterology

New & Established Patients Call

(414) 955-6660

I pride myself on establishing a meaningful relationship with all patients I care for. As an interventional endoscopist, I often see patients that are referred from other gastroenterologists and physicians for complex endoscopic problems. This occasionally results in meeting the patient for the first time right before his/her procedure. I make every effort to explain the problem, and the treatment plan to the patient and his/her loved one(s) so that they understand what we propose to do and what the next steps will be. Additionally, I place a high value on multidisciplinary care and collaboration. Many patients I treat are also cared for by other specialists and in these circumstances, input from the entire treatment team is imperative to optimize patient outcomes. Further, some conditions such as pancreatic fluid collections have various treatment options that span disciplines such as hepato-pancreaticobiliary surgery and interventional radiology. Only when we discuss and plan treatment strategies in a collaborative manner, are we able to achieve the best outcomes for our patients.

Overview

Diseases and Conditions

Barrett's Esophagus
Bile Duct Cancer
Esophageal Cancer
Pancreatic Cancer
Pancreatitis
Pancreatobiliary Disease
Polyps
Bile Duct Disorders
Pancreatic Fluid Collections

Treatments and Services

Stenting of the GI Tract
ERCP
Endoscopic Ultrasound (EUS)
Endoscopic Mucosal Resection (EMR)
Interventional Endoscopy
Endoscopic Suturing
Endotherapy for Barrett's Esophagus
Endoscopic Management of Perforations, Leaks and Fistulas

Patients Ages Seen

Adult
Senior

Languages

English

Hospital Affiliations

Froedtert Hospital – Milwaukee
Zablocki VA Medical Center – Milwaukee

Board Certifications

Gastroenterology
Internal Medicine

Clinic Locations

Gastroenterology and Hepatology - Froedtert Hospital

8850 William Coffey Drive
Milwaukee, WI 53226
(414) 805-3310
Get Directions

Biography

Dr. Smith did his Gastroenterology and Hepatology training at the Medical College of Wisconsin. After pursuing subspecialty training in interventional endoscopy at Washington University School of Medicine in St. Louis, and spending three years on faculty at Case Western Reserve University School of Medicine in Cleveland, he returned to MCW in 2020 to join the faculty in the Division of Gastroenterology and Hepatology. His clinical expertise is interventional endoscopy and pancreaticobiliary disorders. Dr. Smith has extensive research interests in many fields of gastrointestinal endoscopy and his primary research focus at MCW is to design and conduct clinical trials and other high-impact studies that will help shape best practices of gastrointestinal endoscopy in the future.

Education and Training

Doctor of Osteopathic Medicine - Michigan State University College of Osteopathic Medicine - East Lansing, MI (2009)
Residency in Internal Medicine - University of Chicago Pritzker School of Medicine/NorthShore University HealthSystem - Evanston, IL (2009-2012)
Chief Resident - Internal Medicine - University of Chicago Pritzker School of Medicine/NorthShore University HealthSystem - Evanston, IL (2012-2013)
Fellowship in Gastroenterology and Hepatology - Medical College of Wisconsin Affiliated Hospitals - Milwaukee, WI (2013-2016)
Fellowship in Interventional Endoscopy - Washington University School of Medicine - St. Louis, MO (2016-2017)

Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set.

(Elmunzer BJ, Zhang J, Coté GA, Edmundowicz SA, Wani S, Shah R, Bang JY, Varadarajulu S, Singh VK, Khashab M, Kwon RS, Scheiman JM, Willingham FF, Keilin SA, Papachristou GI, Chak A, Slivka A, Mullady D, Kushnir V, Buxbaum J, Keswani R, Gardner TB, Forbes N, Rastogi A, Ross A, Law J, Yachimski P, Chen YI, Barkun A, Smith ZL, Serrano J, Petersen B, Wang AY, Saltzman JR, Spitzer RL, Ordiah C, Spino C, Foster LD, Durkalski-Mauldin V, SVI Study Group*.) Am J Gastroenterol. 2024 Aug 27 PMID: 39207308 SCOPUS ID: 2-s2.0-85202550525 08/31/2024
Trainee Participation and Outcomes in High-risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the Stent Versus Indomethacin Trial.

(Wani S, Zhang J, Foster LD, Durkalski-Mauldin V, Elmunzer BJ, Stent Versus Indomethacin (SVI) Study Group.) Clin Gastroenterol Hepatol. 2024 Jul 31 PMID: 39089516 SCOPUS ID: 2-s2.0-85203410003 08/02/2024
Incidence, Predictors, and Outcomes of Clinically Significant Post-ERCP Bleeding: a Contemporary Multi-center Study.

(Bishay K, Ruan Y, Barkun AN, Chen YI, Singh A, Hookey L, Arya N, Calo NC, Grover SC, Siersema PD, Thosani N, Darvish-Kazem S, Siegal D, Bass S, Cole M, Lei Y, Li S, Mohamed R, Turbide C, Chau M, Howarth M, Cartwright S, Koury HF, Nashad T, Meng ZW, Tepox-Padrón A, Kayal A, González-Moreno E, Brenner DR, Smith ZL, Keswani RN, Elmunzer BJ, Wani S, Bridges RJ, Hilsden RJ, Heitman SJ, Forbes N.) Am J Gastroenterol. 2024 Jul 05 PMID: 38976522 SCOPUS ID: 2-s2.0-85200219086 07/08/2024
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19.

(Elmunzer BJ, Palsson OS, Forbes N, Zakaria A, Davis C, Canakis A, Qayed E, Bick B, Pawa S, Tierney WM, McLeod CG, Taylor J, Patel H, Mendelsohn RB, Bala G, Sloan I, Merchant AA, Smith ZL, Sendzischew Shane MA, Aroniadis OC, Ordiah CO, Ruddy JM, Simren M, Tack J, Drossman D, Rome Foundation Research Institute and the North American Alliance for the Study of Digestive Manifestations of COVID-19.) Clin Gastroenterol Hepatol. 2024 May;22(5):1098-1107.e3 PMID: 37995983 SCOPUS ID: 2-s2.0-85180336940 11/24/2023
Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.

(Elmunzer BJ, Foster LD, Serrano J, Coté GA, Edmundowicz SA, Wani S, Shah R, Bang JY, Varadarajulu S, Singh VK, Khashab M, Kwon RS, Scheiman JM, Willingham FF, Keilin SA, Papachristou GI, Chak A, Slivka A, Mullady D, Kushnir V, Buxbaum J, Keswani R, Gardner TB, Forbes N, Rastogi A, Ross A, Law J, Yachimski P, Chen YI, Barkun A, Smith ZL, Petersen B, Wang AY, Saltzman JR, Spitzer RL, Ordiah C, Spino C, Durkalski-Mauldin V, SVI Study Group.) Lancet. 2024 Feb 03;403(10425):450-458 PMID: 38219767 PMCID: PMC10872215 SCOPUS ID: 2-s2.0-85183679654 01/15/2024
Incidence of Esophageal Adenocarcinoma, Mortality, and Esophagectomy in Barrett's Esophagus Patients Undergoing Endoscopic Eradication Therapy.

(Smith ZL, Thorgerson AM, Dawson AZ, Wani S.) Dig Dis Sci. 2023 Dec;68(12):4439-4448 PMID: 37863992 SCOPUS ID: 2-s2.0-85174546982 10/21/2023
Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer.

(Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S.) Ann Surg. 2023 Dec 01;278(6):e1224-e1231 PMID: 37078282 SCOPUS ID: 2-s2.0-85176508848 04/20/2023
ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

(Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3022 PMID: 36877324 SCOPUS ID: 2-s2.0-85152164746 03/07/2023
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

(Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3013-3021 PMID: 36788189 SCOPUS ID: 2-s2.0-85147934173 02/15/2023
The incidence of new mental health disorders after acute pancreatitis: A large, propensity-matched, observational study.

(Khoja K, Sadiq O, Chisholm PR, Dua KS, Madhavan S, Smith ZL.) Pancreatology. 2023 Mar;23(2):163-170 PMID: 36710225 SCOPUS ID: 2-s2.0-85148705757 01/30/2023
ERCP-related adverse events: incidence, mechanisms, risk factors, prevention, and management.

(Rivas A, Pherwani S, Mohamed R, Smith ZL, Elmunzer BJ, Forbes N.) Expert Rev Gastroenterol Hepatol. 2023;17(11):1101-1116 PMID: 37899490 SCOPUS ID: 2-s2.0-85175702275 10/30/2023
Consensus-based development of a causal attribution system for post-ERCP adverse events.

(Forbes N, Elmunzer BJ, Keswani RN, Hilsden RJ, Hall M, Anderson JT, Arvanitakis M, Chen YI, Duloy A, Elta GH, Maranki JL, Mergener K, Petersen BT, Sethi A, Siersema PD, Smith ZL, Telford JJ, Tse F, Cotton PB, Wani S.) Gut. 2022 Jul 11 PMID: 35817552 SCOPUS ID: 2-s2.0-85138182417 07/12/2022